Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
Glucotrack (GCTK) delivers innovative diabetes management solutions through non-invasive and implantable glucose monitoring technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and market developments.
Access real-time information about regulatory milestones, product certifications, and strategic partnerships. Our curated feed includes earnings reports, clinical trial outcomes, and technology updates directly impacting GCTK's position in the medical device sector.
Key coverage areas include FDA/EU regulatory progress, implantable CBGM system trials, and commercial expansion initiatives. Bookmark this page for streamlined tracking of Glucotrack's progress in revolutionizing blood glucose measurement through cutting-edge ultrasound and electromagnetic technologies.
Glucotrack (Nasdaq: GCTK) has announced its participation in the FORGETDIABETES bionic pancreas initiative, funded by the EU's Horizon 2020 program with €75 Billion. The project aims to develop a long-term automated insulin delivery system for type 1 diabetes patients.
Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.
Led by Dr. Claudio Cobelli from the University of Padova, the project includes partners from Italy, Germany, and France. The initiative aims to transform diabetes management from a constant-attention disease to a manageable lifestyle condition, similar to wearing long-term contact lenses.
Glucotrack (NASDAQ: GCTK) has partnered with OneTwo Analytics AB to analyze clinical study data for its Continuous Blood Glucose Monitor (CBGM) using AI-driven analytics. The collaboration aims to evaluate the performance and clinical value of Glucotrack's innovative CBGM technology.
Unlike traditional monitors that measure glucose in interstitial fluid, Glucotrack's CBGM is a long-term implantable device that measures glucose directly from blood, providing real-time readings without lag time. The device operates without external components and is designed to offer three years of continuous monitoring.
Through this partnership, OneTwo Analytics will apply their expertise in diabetes data analysis to identify and assess the long-term benefits of the CBGM technology. The collaboration focuses on developing a comprehensive ecosystem combining blood glucose insights, risk stratification data, patient engagement tools, and clinical dashboards.
Glucotrack (NASDAQ: GCTK) reported its full year 2024 financial results, marking a transformative year as the company advanced from preclinical to clinical stage. The company successfully completed its first human clinical study of the continuous blood glucose monitor (CBGM), which met its primary endpoint with no serious adverse events.
Key financial highlights include:
- R&D expenses increased to $9.5M (vs $4.7M in 2023)
- Marketing and administrative expenses rose to $5.1M (vs $2.4M in 2023)
- Net loss widened to $22.6M (vs $7.1M in 2023)
- Cash position of $5.6M as of December 31, 2024
- Secured $16.3M through multiple funding rounds from November 2024 through March 2025
The company expects FDA IDE approval for their CBGM technology in Q4 2025 and plans to commence a long-term multicenter feasibility study in Australia in Q2 2025. Their CBGM technology will be the first fully implantable system with a multi-year monitoring capability and real-time measuring features.
Glucotrack (NASDAQ: GCTK) has announced it will present safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (CBGM) system at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Amsterdam.
The company's CBGM technology is a long-term implantable device designed to last three years with no on-body external component. Unlike traditional monitors that measure glucose in interstitial fluid, Glucotrack's system measures glucose directly from the blood, potentially offering greater accuracy and real-time monitoring.
The presentation will feature results from an early feasibility study evaluating the intravascular CBGM in adults with diabetes mellitus. The study aims to demonstrate the safety, feasibility, and performance of the device. The company plans to advance its clinical program with an upcoming chronic implant study.
Glucotrack (Nasdaq: GCTK) has appointed Dr. Guillermo Umpierrez to its Medical Advisory Board. Dr. Umpierrez, a Professor of Medicine at Emory University and past president of the American Diabetes Association for Medicine and Science, brings extensive clinical and research expertise in diabetes care.
The company is developing a novel Continuous Blood Glucose Monitoring (CBGM) technology with unique features including:
- Direct blood glucose measurement without interstitial fluid lag time
- 3-year sensor life
- No wearable component
- Less intrusive monitoring approach
Dr. Umpierrez, who has published over 500 scientific manuscripts and received numerous awards, will provide strategic guidance as Glucotrack advances its CBGM system through clinical development, following encouraging first-in-human studies.
Glucotrack (Nasdaq: GCTK), a medical technology company focused on diabetes technologies, has announced the pricing of a 'best efforts' public offering of approximately 2.6 million shares of common stock at $1.15 per share. The offering is expected to generate gross proceeds of approximately $3.0 million before deducting placement fees and expenses.
The closing is anticipated to occur around February 5, 2025, subject to customary closing conditions. Dawson James Securities is serving as the sole placement agent for this offering, which is being conducted pursuant to an effective S-3 registration statement previously declared effective by the SEC on October 3, 2024.
Glucotrack (NASDAQ: GCTK) has successfully completed its first human clinical study of a Continuous Blood Glucose Monitor (CBGM). The study, conducted over four days in a hospital setting with six diabetes patients, met its primary endpoint with no procedure or device-related serious adverse events reported.
The CBGM sensor lead was placed in the subclavian vein through a percutaneous procedure, representing the first real-time continuous blood glucose monitor placed in this location. This approach offers direct blood glucose measurement, potentially overcoming limitations of traditional monitors that measure glucose in interstitial fluid.
The device is designed for three years of continuous monitoring with no external body components. While the study focused on safety and procedural aspects rather than sensor accuracy, the system performed similarly to previous animal studies. The successful placement and removal procedures were performed by interventional cardiologists, with monitoring continuing through seven days post-removal.
Glucotrack (NASDAQ: GCTK) has announced a 1-for-20 reverse stock split effective February 4, 2025. The company's outstanding common stock will be reduced from 155,491,473 to approximately 7,774,574 shares, with stockholders' ownership percentages remaining unchanged except for fractional shares, which will be rounded up to the next whole share.
The reverse split, approved by stockholders on January 3, 2025, and ratified by the Board on January 28, 2025, aims to bring Glucotrack into compliance with Nasdaq's $1.00 minimum bid price requirement and attract institutional investors. The company's stock will continue trading on Nasdaq under the symbol 'GCTK' with a new CUSIP number 45824Q705.
VStock Transfer, will serve as the exchange agent, managing the automatic share adjustment process and sending transaction statements to stockholders. Those holding shares through brokers will have their positions automatically adjusted according to their broker's processes.
Glucotrack (Nasdaq: GCTK) has appointed Peter C. Wulff as Chief Financial Officer, effective immediately. Wulff brings over 35 years of financial management experience in the emerging growth life sciences sector, with expertise in both public and private companies.
Wulff's track record includes successful capital raising through public and private equity offerings, debt financing, and strategic business transactions. He previously served as CFO at Biological Dynamics, Inc. and JenaValve Technology, Inc., where he managed the company's corporate relocation from Germany and various capital raise transactions. His experience also includes financial leadership roles at Alphatec Spine Holdings, Artes Medical, CryoCor, and Pure Biosciences.
The appointment aims to support Glucotrack's commercialization of its continuous blood glucose monitor for people with diabetes, with focus on driving financial excellence and advancing the company's strategic vision.
Glucotrack (Nasdaq: GCTK) has achieved ISO 13485:2016 certification from the British Standards Institute (BSI), marking a significant milestone in its development of continuous blood glucose monitoring technology. The certification validates the company's quality management system for medical device design and development.
The achievement follows successful completion of Stage I and Stage II Assessments by BSI, confirming Glucotrack's compliance with ISO 13485:2016 standards. This internationally recognized certification is particularly significant given the FDA's 2024 Quality Management System Regulation Final Rule, which aligns U.S. requirements with global standards through ISO 13485 adoption.
CEO Paul V. Goode emphasized this certification's importance in their journey toward delivering high-quality Continuous Blood Glucose Monitor (CBGM) products for people with diabetes, highlighting the company's commitment to quality and regulatory excellence.
FAQ
What is the current stock price of Glucotrack (GCTK)?
What is the market cap of Glucotrack (GCTK)?
